Navigation Links
QIAGEN and Pfizer Partner to Develop Companion Diagnostic for Novel Compound in Global Clinical Trials for Lung Cancer
Date:8/16/2011

http://www.qiagen.com/.

Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results, including without limitation its expected operating results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between business segments, the commercial development of markets for our products in applied testing, personalized healthcare, clinical research, proteomics, women's health/HPV testing and nucleic acid-based molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furn
'/>"/>

SOURCE QIAGEN N.V.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. QIAGEN Completes Second U.S.Submission for Companion Diagnostic to Guide Treatment Decisions in Colorectal Cancer
2. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) Fourth Quarter and Year-End 2009 Financial Results Call Set for February 9
3. QIAGEN Acquires ESE GmbH
4. WuXi AppTec and QIAGEN Enter into Partnership Agreement for Molecular Biomarker Development
5. Ending Cervical Cancer Featured at Summit; QIAGEN CEO Issues a Call to Global Women Leaders
6. Study Finds QIAGENs HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap
7. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) First Quarter 2008 Financial Results Call Set for May 6
8. QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Womens Health Issues
9. QIAGEN N.V. (Nasdaq: QGEN) Invites You to Join Its Third Quarter 2007 Earnings Conference Call on the Web
10. Pfizer Receives Complete Response Letter from FDA for REMOXY®
11. BioMarin Agrees to Acquire Biologics Manufacturing Plant in Ireland from Pfizer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , Sept. 1, 2015  AccuTec Blades, Inc. today ... Industrial Blades division.  EPC announced in May 2015 its ... Verona, Virginia and Obregon, ... the sale process. Rick Gagliano ... AccuTec Blades said, "Our new name, AccuTec Blades, reflects ...
(Date:9/1/2015)... , Sept. 1, 2015 Nevro Corp. ... that is providing innovative evidence-based solutions for the treatment ... submitted its preliminary response to the Patent Trial and ... inter partes review (IPR), filed by a unit ... claims in U.S. Patent No. 8,359,102 (the ,102 patent). The ...
(Date:9/1/2015)... YEHUDA, Israel , Sept. 1, 2015 ... ), a leading innovator of less invasive, miniaturized circulatory ... heart failure, announced today that it has entered into ... . ("Valtech").  Valtech is a privately held company that ... valve repair and replacement devices for the treatment of ...
Breaking Medicine Technology:AccuTec Blades, Inc. Announces Acquisition of Industrial Blades Division from Edgewell Personal Care Company 2Nevro Announces Submission of Preliminary Response to the Patent Trial and Appeals Board 2HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 2HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 3HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 4HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 5HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 6HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 7HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 8HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 9HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 10
... March 30, 2011 Regado Biosciences, a privately held ... control agents, announced that David J. Mazzo, PhD, President ... Company,s 10th Annual Healthcare Conference at the New York ... 6, 2011 at 11:20 a.m. EDT.  The presentation will ...
... Inc. (Nasdaq: ABAX ), a medical products company ... chairman and chief executive officer,  will present at the 10th ... 8:40 a.m. ET. The conference will be held at the ... About Abaxis Abaxis develops, manufactures and markets portable blood ...
Cached Medicine Technology:Regado Biosciences to Present at the Needham & Company's 10th Annual Healthcare Conference in New York City 2Regado Biosciences to Present at the Needham & Company's 10th Annual Healthcare Conference in New York City 3
(Date:9/1/2015)... ... September 01, 2015 , ... Royal River Natural Foods, ... that followed men and women for 19 years and found that, among those who ... take multivitamins. , The report is part of the September 2015 issue of “Natural ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... Nelson, D.O., has joined its medical management team as an Associate Medical Director. ... all sizes and types in the U.S. and abroad. , Dr. Nelson ...
(Date:9/1/2015)... D.C. (PRWEB) , ... September 01, 2015 , ... Two ... better cross cultural relations through food and dining. , Recently named “the next ... and Luigi Diotaiuti are known for telling the whole story behind food and reclaiming ...
(Date:9/1/2015)... ... September 01, 2015 , ... SC&H Group, a leading ... includes being named a “Best of the Best” firm in the U.S., as well ... the “Best of the Best” in the U.S., selected exclusively on performance in specific ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... is now available. With the Connectivity Kit, EasySampler data is automatically ... lab reactor control experiment, on a touchscreen platform. , EasySampler fully automates ...
Breaking Medicine News(10 mins):Health News:New Study Finds Multivitamins Extend Life After Stroke, Retailer Reports 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 3Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 2Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 3Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 4Health News:SC&H Group Receives Multiple Honors from INSIDE Public Accounting 2Health News:New Technology Allows Unattended Sampling and Synthesis of Chemical Reactions 2Health News:New Technology Allows Unattended Sampling and Synthesis of Chemical Reactions 3
... fibroids, who until now had only an option of a ... of shrinking the fibroid with the drug Mifepristone. Lead researcher ... and vexing problem in women and fibroid relief accounts for ... are symptomatic could have back pain, pain with intercourse, problems ...
... for a long time to its ultraviolet rays, has always been ... German scientists has shown that even moderate sun exposure can result ... skin cancer. Exposure to sun has been shown as the main ... and melanoma, the rarest type of skin cancer, is much weaker. ...
... genetic mutation called C150T transition in people over 100 years ... This genetic mutation was found in the mitochondrial DNA of ... 52 Italian centenarians. The researchers found that 17 per cent ... in only 3.4 per cent of 117 control subjects under ...
... method by which arterial stiffness in elderly hypertensive patients ... is measured by computerized oscillometry at the upper arm. ... Japan studied 42 patients, 26 of whom were over ... and compared it with other methods of evaluating arterial ...
... research project carried out by Juliette van den Dolder at ... can be grown into bone fractures with the help of ... a titanium mesh scaffold into a bone fracture in a ... This resulted in new bone growth being stimulated by the ...
... of same-sex twins in which only one twin had smoked ... theory" that pot can lead to harder drugs. The study ... genetic makeup and all the participants were 30 years of ... teenage drug use. The researchers found that those who were ...
Cached Medicine News:Health News:Treatment for fibroids with "Abortion Pill" 2Health News:Bones repair themselves with bone marrow cells 2
ACRYSOF® Posterior Chamber Intraocular Lenses are indicated for the replacement of the human lens to achieve visual correction of aphakia in patients sixty years and older. These lenses are inten...
... Chamber Lenses: The Bausch & Lomb PMMA Posterior ... for primary implantation for the visual correction of ... older where a cataractous lens has been removed ... to be placed in the ciliary sulcus or ...
Multipiece PMMA IOL - Sulcus Fixation....
Hydrophobic Acrylic Intraocular Lens (Refractive and Bifocal). Anterior Chamber Lens....
Medicine Products: